IP Library › Granted Patent US 12667613
Granted Patent B2
US 12667613 · App. 18/004,494 · Granted Jun 30, 2026

Nucleoside-modified RNA for inducing an immune response against SARS-CoV-2

Inventors: Norbert Pardi (Philadelphia, PA); Drew Weissman (Wynnewood, PA)
Assignee: The Trustees of the University of Pennsylvania
A61K39/215A61K9/0019A61P31/14A61K2039/53A61K2039/6018
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12667613
App. No.
18/004,494
Granted
Jun 30, 2026
Kind
B2
Abstract

The present invention relates to compositions and methods for inducing an adaptive immune response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a subject. In certain embodiments, the present invention provides a composition comprising a nucleoside-modified nucleic acid molecule encoding a SARS-CoV-2 antigen, adjuvant, or a combination thereof. For example, in certain embodiments, the composition comprises a vaccine comprising a nucleoside-modified nucleic acid molecule encoding a SARS-CoV-2 antigen, adjuvant, or a combination thereof.

Claims (12)

1 . A composition for inducing an immune response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a subject, the composition comprising at least one isolated nucleoside-modified mRNA encoding at least one SARS-CoV-2 antigen, wherein the at least one nucleoside modified mRNA comprises a nucleotide sequence transcribed from a nucleotide sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 7 and SEQ ID NO: 8.

2 . The composition of claim 1 , wherein the at least one isolated nucleoside-modified mRNA comprises pseudouridine or 1-methyl-pseudouridine.

3 . The composition of claim 1 , wherein the at least one isolated nucleoside-modified mRNA is a purified nucleoside-modified mRNA.

4 . The composition of claim 1 , wherein the composition further comprises an adjuvant.

5 . The composition of claim 1 , further comprising a lipid nanoparticle (LNP), wherein the at least one nucleoside-modified mRNA is encapsulated within the LNP.

6 . The composition of claim 1 , wherein the composition is a vaccine.

7 . A method of inducing an adaptive immune response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a subject comprising administering to the subject an effective amount of the composition of claim 1 .

8 . The method of claim 7 , wherein the at least one isolated nucleoside-modified mRNA comprises pseudouridine or 1-methyl-pseudouridine.

9 . The method of claim 7 , wherein the at least one isolated nucleoside-modified RNA is a purified nucleoside-modified mRNA.

10 . The method of claim 7 , wherein the method further comprises administering to the subject an effective amount of an adjuvant.

11 . The method of claim 7 , wherein the composition further comprises a lipid nanoparticle (LNP), wherein the at least one nucleoside modified mRNA is encapsulated within the LNP.

12 . The method of claim 7 , wherein the composition is administered by a delivery route selected from the group consisting of intradermal, subcutaneous, inhalation, intranasal, and intramuscular.